Regeneron

News

Early result backs Regeneron’s deafness gene therapy

Regeneron’s gene therapy for a profound form of deafness affecting children, DB-OTO, has shown the first signs that it can improve hearing in a clinical trial.

News

FDA clears Roche’s Vabysmo for retinal vein occlusion

Roche has claimed a third approval from the FDA for its eye disease therapy Vabysmo – already its fastest-growing product – that could make it an option for hundreds of th

News

FDA starts swift review of Regeneron’s CD20 bispecific

The FDA has started a priority review of Regeneron’s CD20xCD3 bispecific antibody odronextamab, seeking a broader label than other drugs in the class.

News

CHMP backs Almirall’s eczema therapy lebrikizumab

Almirall is within sniffing distance of EU approval for its IL-13 inhibitor lebrikizumab for atopic dermatitis, setting up a challenge to Sanofi and Regeneron’s market-lea

News

US sets aside $1.4bn for COVID as new variant emerges

The Biden administration has allocated $1.4 billion to new COVID-19 vaccines and drugs, as new SARS-CoV-2 variant BA.2.86 has started spreading in the US.

News

Regeneron gets FDA blessing for CHAPLE drug Veopoz

Patients with the ultra-rare disease CHAPLE now have their first FDA-approved therapy, after the regulator approved Regeneron's pozelimab for people aged one and over with

Early result backs Regeneron’s deafness gene therapy

FDA clears Roche’s Vabysmo for retinal vein occlusion

FDA starts swift review of Regeneron’s CD20 bispecific

CHMP backs Almirall’s eczema therapy lebrikizumab

US sets aside $1.4bn for COVID as new variant emerges

Regeneron gets FDA blessing for CHAPLE drug Veopoz

On genomics, NGS, and doing much more good than bad, with Ma...

How to meet your physicians where they are online

Regeneron

Editor's Picks